Palmitoylethanolamide (CAS 544-31-0)
Palmitoylethanolamide is an endogenous. It is a weak ligand 1 (CB1) and 2 (CB2) receptors. It has been found to inhibit FAAH (fatty acid amide hydrolase).
Palmitoylethanolamide exhibits anti-nociceptive, anti-inflammatory, anti-convulsant and immunosuppresant activity.
Palmitoylethanolamide acts by binding to an unidentified receptor that is similar to CB2. It also acts as a selective activator of the GPR55 receptor. In addition, this compound directly activates PPARα, producing an anti-inflammatory response.
Function : Palmitoylethanolamide exhibits anti-nociceptive, anti-inflammatory, anti-convulsant and immunosuppresant activity
It has been found useful in a variety of chronic diseases, amongst others in severe neuropathic pain, sciatic pain, prostate pain, pain after stroke and in MS and pelvic pain. Side effects are neglectable, due to the fact that this molecule is part of our own body. It has special analgesic properties, and in sciatic pain for instance, it is much more effective compared to the chemical analgesic Lyrica (pregabaline);
It has been proven to be effective and safe in many different disorders, from chronic pains up to flu and common cold, due to its intrinsic anti-inflammatory and analgesic properties.